{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:12:31Z","timestamp":1789132351685,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent an alternative nonfactor therapy for select patients with HB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021944","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T17:43:53Z","timestamp":1720633433000},"page":"1230-1235","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab"],"prefix":"10.1182","volume":"144","author":[{"given":"Kyumin","family":"Lee","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Q.","family":"Chau","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8009-2886","authenticated-orcid":false,"given":"Yani B.","family":"Suber","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-7870","authenticated-orcid":false,"given":"Anna R.","family":"Sternberg","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson M.","family":"Pishko","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"3Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay G.","family":"Bhoj","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-4231","authenticated-orcid":false,"given":"Bhavya S.","family":"Doshi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"3Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-4140","authenticated-orcid":false,"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"3Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024091215212250300_bib1","volume-title":"GeneReviews\u00ae","author":"Konkle","year":"1993"},{"key":"2024091215212250300_bib2","volume-title":"GeneReviews\u00ae","author":"Konkle","year":"1993"},{"key":"2024091215212250300_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(03)00025-0","article-title":"Activation of factor VIII and mechanisms of cofactor action","volume":"18","author":"Fay","year":"2004","journal-title":"Blood Rev"},{"issue":"10","key":"2024091215212250300_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"2024091215212250300_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024091215212250300_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024091215212250300_bib7","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with\u00a0moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"18","key":"2024091215212250300_bib8","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"key":"2024091215212250300_bib9","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.bcmd.2020.102530","article-title":"The potential role of emicizumab prophylaxis in severe von Willebrand disease","volume":"87","author":"Barg","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"21","key":"2024091215212250300_bib10","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2024091215212250300_bib11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2016-09-738641","article-title":"Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations","volume":"129","author":"Branchini","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024091215212250300_bib12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2005-03-1307","article-title":"Aminoglycoside suppression of nonsense mutations in severe hemophilia","volume":"106","author":"James","year":"2005","journal-title":"Blood"},{"issue":"23","key":"2024091215212250300_bib13","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2024091215212250300_bib14","doi-asserted-by":"crossref","first-page":"e128683","DOI":"10.1172\/jci.insight.128683","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"2024091215212250300_bib15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jtha.2023.02.005","article-title":"An updated interactive database\u00a0for 1692 genetic variants in coagulation factor IX provides detailed insights into hemophilia B","volume":"21","author":"Xu","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024091215212250300_bib16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2024091215212250300_bib17","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/bloodadvances.2021005874","article-title":"SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa\/IXa","volume":"6","author":"Childers","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2024091215212250300_bib18","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1042\/BCJ20160336","article-title":"Releasing the brakes in coagulation factor IXa by co-operative maturation of the substrate-binding site","volume":"473","author":"Kristensen","year":"2016","journal-title":"Biochem J"},{"issue":"6","key":"2024091215212250300_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jth.15286","article-title":"Mapping the zymogen to protease transition in FIXa","volume":"19","author":"Sheehan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"pt 2","key":"2024091215212250300_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/bj3390217","article-title":"Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are FVIII-interactive sites involved in stimulation of enzyme activity","volume":"339","author":"Kolkman","year":"1999","journal-title":"Biochem J"},{"issue":"9","key":"2024091215212250300_bib21","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1073\/pnas.82.9.2847","article-title":"Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX","volume":"82","author":"McGraw","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2024091215212250300_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A\u00a0hemophilia A mouse model for the in\u00a0vivo assessment of emicizumab function","volume":"136","author":"Ferriere","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024091215212250300_bib23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in\u00a0vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2024091215212250300_bib24","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"16","key":"2024091215212250300_bib25","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/11\/1230\/2241564\/blood_bld-2023-021944-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/11\/1230\/2241564\/blood_bld-2023-021944-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:33:25Z","timestamp":1726155205000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/11\/1230\/516932\/Enhanced-procoagulant-activity-of-select"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021944","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}